C. S. Fuchs Et Al. , "Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial," GASTRIC CANCER , vol.25, no.1, pp.197-206, 2022
Fuchs, C. S. Et Al. 2022. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. GASTRIC CANCER , vol.25, no.1 , 197-206.
Fuchs, C. S., ÖZGÜROĞLU, M., Bang, Y., Di Bartolomeo, M., Mandala, M., Ryu, M., ... Fornaro, L.(2022). Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. GASTRIC CANCER , vol.25, no.1, 197-206.
Fuchs, Charles Et Al. "Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial," GASTRIC CANCER , vol.25, no.1, 197-206, 2022
Fuchs, Charles S. Et Al. "Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial." GASTRIC CANCER , vol.25, no.1, pp.197-206, 2022
Fuchs, C. S. Et Al. (2022) . "Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial." GASTRIC CANCER , vol.25, no.1, pp.197-206.
@article{article, author={Charles S. Fuchs Et Al. }, title={Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial}, journal={GASTRIC CANCER}, year=2022, pages={197-206} }